Myriad Genetics experienced a substantial decline in stockholders' equity of 47.5% alongside a significant 31% reduction in total assets, indicating potential major writedowns or restructuring activities.
The dramatic reduction in stockholders' equity coupled with shrinking total assets suggests MYGN may have taken significant impairment charges or asset writedowns during the period. While the company improved its cash position and reduced current liabilities, the overall balance sheet contraction raises questions about asset valuations and potential strategic repositioning.
MYGN's balance sheet reflects substantial contraction, with stockholders' equity falling 47.5% to $368M and total assets declining 31% to $706.6M, suggesting significant writedowns or impairments. However, the company strengthened its liquidity position with cash increasing 46% to $149.6M while reducing current liabilities by 18.5%. SG&A expenses grew modestly by 11.3%, indicating continued investment in operations despite the balance sheet restructuring.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Cash position surged 46.1% — strong cash generation or capital raise providing significant financial cushion.
Total assets contracted 31.2% — asset sales, write-downs, or balance sheet optimization underway.
Current liabilities reduced — improved short-term financial position and working capital health.
Current assets grew 11.6% — improving short-term liquidity or inventory/receivables build.
SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.
Inventory built 11.3% — monitor whether demand supports this build or if write-downs may follow.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →